Research Article

Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy

Volume: 9 Number: 3 December 1, 2019
  • Fatma Tuba Akdeniz *
  • Seda Güleç Yılmaz
  • Cemil Selim İsbir
  • Yaşar Birkan
  • David Sinan Esensoy
  • Gözde Özcan
  • Atike Tekeli Kunt
  • Turgay İsbir
EN TR

Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy

Abstract

DOI: 10.26650/experimed.2019.19024 Objective: Left ventricular hypertrophy (LVH) accounts for one of the most important independent risk factors for cardiac diseases. In the present study, we investigate the relationship of DNA repair gene polymorphisms and LVH. Material and Method: DNA samples isolated from peripheral blood were genotyped with real-time polymerase chain reaction (RT-PCR) for RRM1 (rs12806698), RRM2 (rs6859180) and ERCC2 (rs13181) genes. Results: Although there were no significant differences for RRM2 (p=0.365) and ERCC2 (p=0.740) genes. RRM1 (A>C) CC genotype was significantly higher in the LVH than control groups (p=0.018). RRM1gene wild type A allele carriers were significantly higher in the healthy controls than the LVH group (p=0.029). Conclusion: RRM1 gene CC genotype could be a risk factor, whereas the RRM1 gene AC genotype and the A allele might play a protective role against LVH. Cite this article as: Akdeniz FT, Güleç Yılmaz S, İsbir CS, Birkan Y, Esensoy DS, Özcan G, et al. Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy. Experimed 2019; 9(3): 99-104.

Keywords

References

  1. 1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation 2017; 135: 146-603. [CrossRef] 2. Messerli FH, Schmieder R. Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986; 31: 192-201. [CrossRef] 3. Davidson, BP, Giraud GD. Left ventricular function and the systemic arterial vasculature: remembering what we have learned. J Am Soc Echocardiogr 2012; 25: 891-94. [CrossRef] 4. Pokharel P, Bella JN. Regression of left ventricular hypertrophy: Lessons from clinical trials. OA Evidence-Based Medicine 2013; 1: 13. https://doi.org/10.13172/2053-2636-1-2-1110. [CrossRef] 5. Elledge SJ, Zhou Z, Allen JB. Ribonucleotide reductase: regulation, regulation, regulation. Trends Biochem Sci 1992; 17: 119-23. [CrossRef] 6. Oh IJ, Ban HJ, Kim KS, Song SY, Na KJ, Kim YH, et al. Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer. Thorac Cancer 2012; 3: 19-26. [CrossRef] 7. Thomson KS, Odom GL, Murry CE, Mahairas GG, Moussavi-Harami F, Teichman SL, et al. Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy. JACC Basic Transl Sci 2016; 1: 666-79. [CrossRef] 8. Korte FS, Dai J, Buckley K, Feest ER, AdamekN, Geeves MA, et al. Upregulation of cardiomyocyte ribonucleotide reductase increases intracellular 2 deoxy-ATP, contractility, and relaxation. J Mol Cell Cardiol 2011; 51: 894-901. [CrossRef] 9. Nowakowski SG, Kolwicz SC, Korte FS, Luo Z, Robinson-Hamm JN, Page JL, et al. Transgenic overexpression of ribonucleotide reductase improves cardiac performance. Proc Natl Acad Sci U S A 2013; 110: 6187-92. [CrossRef] 10. Kadota S, Carey J, Reinecke H, Leggett J, Teichman S, Laflamme MA, et al. Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure. Eur J Heart Fail 2015; 17: 772-81. [CrossRef] 11. Cervelli T, Borghini A, Galli A, Andreassi MG. DNA damage and repair in atherosclerosis: current insights and future perspectives. Int J Mol Sci 2012; 13:16929-44. [CrossRef] 12. Gallaugher LD, Henry JC, Kearns PN, Elford HL, Bergdall VK, Cardaunel AJ. Ribonucleotide reductase inhibitors reduce atherosclerosis in a double-injury rabbit model. Comp Med 2009; 59: 567-72. 13. Nowsheen S, Yang ES. The Intersection Between Dna Damage Response And Cell Death Pathways. Exp Oncol 2012; 34: 243-54. 14. Choi YH, Cowan DB, Moran AM, Colan SD, Stamm C, Takeuchi K, et al. Myocyte apoptosis occurs early during the development of pressure-overload hypertrophy in infant myocardium. J Thorac Cardiovasc Surg 2009; 137: 1356-62. [CrossRef] 15. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, et al. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer 2005; 47: 183-92. [CrossRef] 16. Garavaglia GE, Messerli FH, Schmieder RE, Nunez BD, Oren S. Sex differences in cardiac adaptation to essential hypertension. Eur Heart J 1989; 10: 1110-4. [CrossRef] 17. Gradman AH, Alfayoumi F. From Left Ventricular Hypertrophy to Congestive Heart Failure: Management of Hypertensive Heart Disease. Prog Cardiovasc Dis 2006; 48: 326-34. [CrossRef]

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Authors

Fatma Tuba Akdeniz * This is me
Andorra

Seda Güleç Yılmaz This is me
Andorra

Cemil Selim İsbir This is me
Andorra

Yaşar Birkan This is me
Andorra

David Sinan Esensoy This is me
Andorra

Gözde Özcan This is me
Andorra

Atike Tekeli Kunt This is me
Andorra

Turgay İsbir This is me
Andorra

Publication Date

December 1, 2019

Submission Date

October 23, 2019

Acceptance Date

-

Published in Issue

Year 2019 Volume: 9 Number: 3

APA
Akdeniz, F. T., Güleç Yılmaz, S., İsbir, C. S., Birkan, Y., Esensoy, D. S., Özcan, G., Tekeli Kunt, A., & İsbir, T. (2019). Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy. Experimed, 9(3), 99-104. https://izlik.org/JA76WK43DW
AMA
1.Akdeniz FT, Güleç Yılmaz S, İsbir CS, et al. Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy. Experimed. 2019;9(3):99-104. https://izlik.org/JA76WK43DW
Chicago
Akdeniz, Fatma Tuba, Seda Güleç Yılmaz, Cemil Selim İsbir, et al. 2019. “Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy”. Experimed 9 (3): 99-104. https://izlik.org/JA76WK43DW.
EndNote
Akdeniz FT, Güleç Yılmaz S, İsbir CS, Birkan Y, Esensoy DS, Özcan G, Tekeli Kunt A, İsbir T (December 1, 2019) Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy. Experimed 9 3 99–104.
IEEE
[1]F. T. Akdeniz et al., “Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy”, Experimed, vol. 9, no. 3, pp. 99–104, Dec. 2019, [Online]. Available: https://izlik.org/JA76WK43DW
ISNAD
Akdeniz, Fatma Tuba - Güleç Yılmaz, Seda - İsbir, Cemil Selim - Birkan, Yaşar - Esensoy, David Sinan - Özcan, Gözde - Tekeli Kunt, Atike - İsbir, Turgay. “Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy”. Experimed 9/3 (December 1, 2019): 99-104. https://izlik.org/JA76WK43DW.
JAMA
1.Akdeniz FT, Güleç Yılmaz S, İsbir CS, Birkan Y, Esensoy DS, Özcan G, Tekeli Kunt A, İsbir T. Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy. Experimed. 2019;9:99–104.
MLA
Akdeniz, Fatma Tuba, et al. “Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy”. Experimed, vol. 9, no. 3, Dec. 2019, pp. 99-104, https://izlik.org/JA76WK43DW.
Vancouver
1.Fatma Tuba Akdeniz, Seda Güleç Yılmaz, Cemil Selim İsbir, Yaşar Birkan, David Sinan Esensoy, Gözde Özcan, Atike Tekeli Kunt, Turgay İsbir. Preliminary Study: DNA Repair Gene Polymorphisms (RRM1, RRM2, ERCC2) In Left Ventricular Hypertrophy. Experimed [Internet]. 2019 Dec. 1;9(3):99-104. Available from: https://izlik.org/JA76WK43DW